FDA Approves Esperion Therapeutics' New Cholesterol Drug
The U.S. Food and Drug Administration announced on Friday afternoon that it had officially approved a new cholesterol-lowering drug developed by Esperion Therapeutics (NASDAQ: ESPR). Nexletol (also known as bempedoic acid) is intended to be used as an add-on treatment for patients already taking cholesterol-lowering drugs such as statins. While millions of Americans take statins, for a significant number of them, these drugs don't work well enough.
Nexletol is recommended for patients with high levels of LDL cholesterol (also known as the "bad" cholesterol) and elevated risk of heart attack or stroke. The once-per-day pill is the first oral non-statin cholesterol drug approved by the FDA in almost two decades. It's also Esperion's first drug to be approved for sale in the U.S. Its 2020 sales are expected to come in at around $33 million.
Image source: Getty Images.
Source Fool.com
